A high expression of methyltransferase EZH2 shortens survival in patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL), according to a study published in the Journal of Experimental Hematology.
In this study, researchers analyzed 161 patients with newly treated PGI-DLBCL from August 2013 to July 2019. They used immunohistochemistry to detect EZH2 expression while comparing both short-term efficacy and long-term survival differences of patients with different levels of EZH2.
Following analysis, the researchers observed that complete response (CR) and overall response (OR) rates of those with high EZH2 expression were markedly lower than those with low EZH2 expression. They noted that the median OS and PFS of EZH2 high-level and low-level expression group was 37, 31 months and 49, 42 months, respectively. Moreover, the cumulative OS and PFS rates of the high-level expression group were appreciably lower compared to patients in the low-level expression group, and the researchers noted the differences were statistically significant (P<0.05).
“In patients with PGI-DLBCL, the high expression of EZH2 significantly reduces the short-term CR and OR rates, which is an independent risk factor for the shortening of long-term OS and PFS rates, and it is independently related to the high expression of H3K27me3 and BCL6,” the researchers concluded.
Keywords: Autograft absolute lymphocyte count, Autologous peripheral blood hematopoietic stem cell transplantation, Diffuse large B-cell Lymphoma